These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 29573334)

  • 21. Regorafenib in the treatment of metastatic colorectal cancer.
    de la Fouchardière C
    Future Oncol; 2018 Sep; 14(22):2239-2246. PubMed ID: 29569472
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Regorafenib inhibited gastric cancer cells growth and invasion via CXCR4 activated Wnt pathway.
    Lin XL; Xu Q; Tang L; Sun L; Han T; Wang LW; Xiao XY
    PLoS One; 2017; 12(5):e0177335. PubMed ID: 28489887
    [TBL] [Abstract][Full Text] [Related]  

  • 23. AZD2171 shows potent antitumor activity against gastric cancer over-expressing fibroblast growth factor receptor 2/keratinocyte growth factor receptor.
    Takeda M; Arao T; Yokote H; Komatsu T; Yanagihara K; Sasaki H; Yamada Y; Tamura T; Fukuoka K; Kimura H; Saijo N; Nishio K
    Clin Cancer Res; 2007 May; 13(10):3051-7. PubMed ID: 17505008
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial.
    Pearson A; Smyth E; Babina IS; Herrera-Abreu MT; Tarazona N; Peckitt C; Kilgour E; Smith NR; Geh C; Rooney C; Cutts R; Campbell J; Ning J; Fenwick K; Swain A; Brown G; Chua S; Thomas A; Johnston SRD; Ajaz M; Sumpter K; Gillbanks A; Watkins D; Chau I; Popat S; Cunningham D; Turner NC
    Cancer Discov; 2016 Aug; 6(8):838-851. PubMed ID: 27179038
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma.
    Liu YJ; Shen D; Yin X; Gavine P; Zhang T; Su X; Zhan P; Xu Y; Lv J; Qian J; Liu C; Sun Y; Qian Z; Zhang J; Gu Y; Ni X
    Br J Cancer; 2014 Mar; 110(5):1169-78. PubMed ID: 24518603
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplification.
    Van Cutsem E; Bang YJ; Mansoor W; Petty RD; Chao Y; Cunningham D; Ferry DR; Smith NR; Frewer P; Ratnayake J; Stockman PK; Kilgour E; Landers D
    Ann Oncol; 2017 Jun; 28(6):1316-1324. PubMed ID: 29177434
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mcl-1 inhibition overcomes intrinsic and acquired regorafenib resistance in colorectal cancer.
    Song X; Shen L; Tong J; Kuang C; Zeng S; Schoen RE; Yu J; Pei H; Zhang L
    Theranostics; 2020; 10(18):8098-8110. PubMed ID: 32724460
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase networks.
    Kataoka Y; Mukohara T; Tomioka H; Funakoshi Y; Kiyota N; Fujiwara Y; Yashiro M; Hirakawa K; Hirai M; Minami H
    Invest New Drugs; 2012 Aug; 30(4):1352-60. PubMed ID: 21655918
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FGFR2 gene amplification and clinicopathological features in gastric cancer.
    Matsumoto K; Arao T; Hamaguchi T; Shimada Y; Kato K; Oda I; Taniguchi H; Koizumi F; Yanagihara K; Sasaki H; Nishio K; Yamada Y
    Br J Cancer; 2012 Feb; 106(4):727-32. PubMed ID: 22240789
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Regorafenib (BAY 73-4506): antitumor and antimetastatic activities in preclinical models of colorectal cancer.
    Schmieder R; Hoffmann J; Becker M; Bhargava A; Müller T; Kahmann N; Ellinghaus P; Adams R; Rosenthal A; Thierauch KH; Scholz A; Wilhelm SM; Zopf D
    Int J Cancer; 2014 Sep; 135(6):1487-96. PubMed ID: 24347491
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Circulating Tumor DNA Analysis Detects
    Jogo T; Nakamura Y; Shitara K; Bando H; Yasui H; Esaki T; Terazawa T; Satoh T; Shinozaki E; Nishina T; Sunakawa Y; Komatsu Y; Hara H; Oki E; Matsuhashi N; Ohta T; Kato T; Ohtsubo K; Kawakami T; Okano N; Yamamoto Y; Yamada T; Tsuji A; Odegaard JI; Taniguchi H; Doi T; Fujii S; Yoshino T
    Clin Cancer Res; 2021 Oct; 27(20):5619-5627. PubMed ID: 34376535
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acquired resistance to LY2874455 in FGFR2-amplified gastric cancer through an emergence of novel FGFR2-ACSL5 fusion.
    Kim SY; Ahn T; Bang H; Ham JS; Kim J; Kim ST; Jang J; Shim M; Kang SY; Park SH; Min BH; Lee H; Kang WK; Kim KM; Park W; Lee J
    Oncotarget; 2017 Feb; 8(9):15014-15022. PubMed ID: 28122360
    [TBL] [Abstract][Full Text] [Related]  

  • 33. FGF18-FGFR2 signaling triggers the activation of c-Jun-YAP1 axis to promote carcinogenesis in a subgroup of gastric cancer patients and indicates translational potential.
    Zhang J; Wong CC; Leung KT; Wu F; Zhou Y; Tong JHM; Chan RCK; Li H; Wang Y; Yan H; Liu L; Wu WKK; Chan MWY; Cheng ASL; Yu J; Wong N; Lo KW; To KF; Kang W
    Oncogene; 2020 Oct; 39(43):6647-6663. PubMed ID: 32934314
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination of dual JAK/HDAC inhibitor with regorafenib synergistically reduces tumor growth, metastasis, and regorafenib-induced toxicity in colorectal cancer.
    Bajpai P; Agarwal S; Afaq F; Al Diffalha S; Chandrashekar DS; Kim HG; Shelton A; Miller CR; Singh SK; Singh R; Varambally S; Nagaraju GP; Manne A; Paluri R; Khushman M; Manne U
    J Exp Clin Cancer Res; 2024 Jul; 43(1):192. PubMed ID: 38992681
    [TBL] [Abstract][Full Text] [Related]  

  • 35. GP369, an FGFR2-IIIb-specific antibody, exhibits potent antitumor activity against human cancers driven by activated FGFR2 signaling.
    Bai A; Meetze K; Vo NY; Kollipara S; Mazsa EK; Winston WM; Weiler S; Poling LL; Chen T; Ismail NS; Jiang J; Lerner L; Gyuris J; Weng Z
    Cancer Res; 2010 Oct; 70(19):7630-9. PubMed ID: 20709759
    [TBL] [Abstract][Full Text] [Related]  

  • 36. KRAS exon 2 mutations influence activity of regorafenib in an SW48-based disease model of colorectal cancer.
    Camaj P; Primo S; Wang Y; Heinemann V; Zhao Y; Laubender RP; Stintzing S; Giessen-Jung C; Jung A; Gamba S; Bruns CJ; Modest DP
    Future Oncol; 2015; 11(13):1919-29. PubMed ID: 26161928
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Acquired JHDM1D-BRAF Fusion Confers Resistance to FGFR Inhibition in
    Sase H; Nakanishi Y; Aida S; Horiguchi-Takei K; Akiyama N; Fujii T; Sakata K; Mio T; Aoki M; Ishii N
    Mol Cancer Ther; 2018 Oct; 17(10):2217-2225. PubMed ID: 30045926
    [No Abstract]   [Full Text] [Related]  

  • 38. Multikinase inhibitor regorafenib inhibits the growth and metastasis of colon cancer with abundant stroma.
    Takigawa H; Kitadai Y; Shinagawa K; Yuge R; Higashi Y; Tanaka S; Yasui W; Chayama K
    Cancer Sci; 2016 May; 107(5):601-8. PubMed ID: 26865419
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Direct binding of microRNA-21 pre-element with Regorafenib: An alternative mechanism for anti-colorectal cancer chemotherapy?
    Chen X; Xie B; Cao L; Zhu F; Chen B; Lv H; Fan X; Han L; Bie L; Cao X; Shen X; Cao F
    J Mol Graph Model; 2017 May; 73():48-53. PubMed ID: 28236743
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synergistic antitumor activity of regorafenib and lapatinib in preclinical models of human colorectal cancer.
    Zhang WJ; Li Y; Wei MN; Chen Y; Qiu JG; Jiang QW; Yang Y; Zheng DW; Qin WM; Huang JR; Wang K; Zhang WJ; Wang YJ; Yang DH; Chen ZS; Shi Z
    Cancer Lett; 2017 Feb; 386():100-109. PubMed ID: 27864115
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.